What are the most common mistakes with ARA-290 (Cibinetide)?
The most common ARA-290 (Cibinetide) mistakes are expecting fast pain relief (cumulative over weeks); stopping too early; underdosing, 1 mg often produces no measurable change. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for ARA-290 (Cibinetide) is limited.
Common ARA-290 (Cibinetide) mistakes
- Expecting fast pain relief (cumulative over weeks)
- Stopping too early
- Underdosing, 1 mg often produces no measurable change
Bloodwork worth tracking
- CBC (no measurable RBC effect, but cheap monitoring if running long)
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Full ARA-290 (Cibinetide) breakdownARA-290 (Cibinetide) what it's used forARA-290 (Cibinetide) side effectsARA-290 (Cibinetide) how to take itARA-290 (Cibinetide) who should avoid itARA-290 (Cibinetide) half-lifeARA-290 (Cibinetide) how long to workARA-290 (Cibinetide) legal statusARA-290 (Cibinetide) how it worksAsk the AI Coach
Last updated 2026-06-15.